Acute Migraine Treatment Market: The acute migraine treatment market can be segmented based on drug type, route of administration, and distribution channel. Drug Type: Triptans: Triptans are commonly prescribed drugs for acute migraine treatment, as they help in relieving pain and other symptoms associated with migraines. CGRP Antagonist: CGRP antagonists are a newer class of drugs that target the calcitonin gene-related peptide involved in migraine pain. NSAID Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) are also commonly used for migraine treatment due to their anti-inflammatory properties. Beta-adrenergic: Beta-adrenergic drugs work by constricting blood vessels and reducing inflammation, which can help alleviate migraine symptoms. Ergot Alkaloids: Ergot alkaloids are another class of drugs that are used for acute migraine treatment, although they are less commonly prescribed compared to other drug types. Others: This category includes various other drugs used for migraine treatment, such as antiemetics or opioids in severe cases. Route of Administration: Oral: Oral medications are the most common route of administration for acute migraine treatment, as they are convenient and easy to take. Injection: Injections are also used for migraine treatment, particularly for faster and more potent relief of symptoms. Others: Other routes of administration, such as nasal sprays or suppositories, may be recommended in certain cases based on patient preference or severity of symptoms. Distribution Channel: Hospital Pharmacies: Hospital pharmacies play a crucial role in providing acute migraine treatment to patients who require immediate care or hospitalization. Retail Pharmacies: Retail pharmacies are important in providing access to migraine medications for individuals seeking treatment on an outpatient basis. Online Pharmacies: Online pharmacies have gained popularity in recent years for providing convenient access to medications for migraine treatment, especially for patients who prefer to order medications online.